Abstract
The aim of this study was to evaluate the efficacy of a 6-month treatment with lanreotide (LAN) (60–90 mg/month) alone and combined with cabergoline (CAB) (1.5-3 mg/week) in 10 acromegalic patients previously demonstrated to be poor responders to octreotide (OCT) (0.6 mg/day) alone and combined with quinagolide (CV) (0.6 mg/day).
All patients had previously undergone unsuccessful surgery and none of them received radiotherapy. Immunohistochemistry showed intense positive GH staining in all adenomas, positive PRL staining in 5 adenomas and faint ACTH or FSH/LH positive staining in other 2 adenomas. Moderately elevated serum PRL levels (35 and 47 ng/ml) were recorded in two patients. Fasting plasma IGF-I and serum GH levels were assayed at baseline and 30, 60, 90 and 120 days after each treatment. Gallbladder ultrasonography and sellar MRI were performed before and after 6 months of OCT and LAN treatments.
After OCT treatment circulating GH and IGF-I levels remained elevated in all patients, while after 3 months of combined OCT+CV treatment, serum GH levels were suppressed (below 2.5 ng/ml) in only 1 patient. Significant increase of the percent GH (83.9±4.3 vs. 70.3±5.6%, p<0.01) and IGF-I suppression (54±4.4 vs. 45.3±5.7, p<0.01) and decrease of the nadir of GH (8.5±1.2 vs. 14.6±1.9 ng/ml, p<0.01) and IGF-I (400.9±32.8 vs. 462.1±45.1 ng/ml) were obtained with the combined treatment when compared to OCT treatment alone. After a 15–30 days wash-out, circulating GH and IGF-I levels significantly increased up to pretreatment level in all patients. After 6 months of treatment with LAN, suppression of serum GH was achieved in 1 patient, but no difference in GH (66.3±6.3%) and IGF-I (43.9±4.6%) suppression was recorded in comparison to OCT treatment. After 3 months of treatment with LAN combined with CAB, suppression of serum GH and normalization of plasma IGF-I levels was achieved in 4 and 5 patients, respectively. Percent suppression of GH (88.1±2.1%) and IGF-I (57.5±2.8%) was significantly greater with the combined treatment than with LAN treatment alone. In the 7 patients with evident residual mass no change was documented by magnetic resonance imaging (MRI). None of the patients withdrew LAN+CAB treatment for poor tolerance, one patient had mild hypotension. Sludge was shown after 6 months of LAN treatment in one patient without notable change after 3 months of LAN+CAB treatment.
In conclusion, the treatment with dopaminergic drugs such as CV and CAB, significantly increased the efficacy of somatostatin analogs, and can be used in combined therapy in poorly responsive patients.
Similar content being viewed by others
References
Melmed S. Acromegaly. N Engl J Med 1990;322:966-977.
Frohman LA. Therapeutic options in acromegaly. J Clin Endocrinol Metab 1991;72:1175-1181.
Melmed S, Ho K, Klibanski A, Reinchlin S, Thorner M. Recent advances in pathology, diagnosis and management of acromegaly. J Clin Endocrinol Metab 1995;80:3395-3402.
Colao A, Merola B, Ferone D, Lombardi G. Acromegaly. J Clin Endocrinol Metab 1997;84:2777-2781.
Melmed S, Dowling H, Frohman L, et al. Consensus statement: benefits versus risks of medical therapy for acromegaly. Am J Med 1994;97:468-473.
Lamberts SWJ, van Der Lely AJ, de Herder WW, Hofland J. Octreotide. N Engl J Med 1996;334:246-254.
Heron I, Thomas F, Dero M, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993;76:721-727.
Chiodini PG, Attanasio R, Cozzi R, et al. CV 205-502 in acromegaly. Acta Endocrinol 1993;128:389-393.
Ferrari C, Paracchi A, Romano C, et al. Long-lasting lowering of serum growth hormoneand prolactin levels by single or repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin Endocrinol 1988;29:467-476.
Lamberts SWJ, Zweens M, Verschoor L, del Pozo E. A comparison among the growth hormone lowering effect of the somatostatin analog, SMS 201-995, bromocriptine and combination of both drugs. J Clin Endocrinol Metab 1986;63:16-19.
Chiodini PG, Cozzi R, Dallabonzana D, et al. Medical treatment of acromegaly with SMS 201-995, a somatostatin analogue: a comparison with bromocriptine. J Clin Endocrinol Metab 1987;64:447-453.
Fløgstad AK, Halse J, Grass P, et al. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab 1994;79:461-465.
Morange I, De Boisvilliers F, Chanson P, et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 1994; 79:145-151.
Marek J, Hana V, Krsek M, Justova V, Catus F, Thomas F. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol 1994;131:20-26.
Giusti M, Gussoni G, Cuttica CM, Giordano G, and the italian multicenter slow release lanreotide study group. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on a Italian multicenter study. J Clin Endocrinol Metab 1996;81:2089-2097.
Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three years follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997; 82:18-22.
Lombardi G, Colao A, Ferone D, et al. CV 205-502 treatment in therapy-resistant acromegalic patients. Eur J Endocrinol 1995;132:559-564.
Fredstorp L, Kutz K, Werner S. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study. Clin Endocrinol 1994; 41:103-108.
Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904-909.
Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to other dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997; 83:876-883.
Jackson SN, Fowler J, Howlett TA. Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin Endocrinol Oxf 1997;46:745-749.
Abs R, Versholst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998;83:374-378.
Colao A, Ferone D, Lastoria S, et al Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab. 1996;81:1356-1362.
Wass JAH. Acromegaly: treatment after 100 years. Br Med J 1993;307:1505-1506.
Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab. 1997;82:3187-3191.
Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:220-240.
Colao A, Ferone D, Marzullo P, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997;82:518-523.
Lamberts SWJ, Liuzzi A, Chiodini PG, Verde S, Klijn JGM, Birkenhäger JC. The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly. Eur J Clin Invest 1982;12:151-155.
Lamberts SWJ, Klijn JGM, van Vroonhoven CCJ, Stefanko SZ, Liuzzi A. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly. Acta Endocrinol 1983;103:446-450.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marzullo, P., Marinò, V., Ferone, D. et al. Efficacy of Combined Treatment with Lanreotide and Cabergoline in Selected Therapy-Resistant Acromegalic Patients. Pituitary 1, 115–120 (1999). https://doi.org/10.1023/A:1009932521242
Issue Date:
DOI: https://doi.org/10.1023/A:1009932521242